These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 28335910)

  • 21. Clinical management and diagnosis of CLN2 disease: consensus of the Brazilian experts group.
    Sampaio LPB; Manreza MLG; Pessoa A; Gurgel-Giannetti J; Coan AC; Júnior HVL; Embiruçu EK; Henriques-Souza AMM; Kok F
    Arq Neuropsiquiatr; 2023 Mar; 81(3):284-295. PubMed ID: 37059438
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapeutic landscape for Batten disease: current treatments and future prospects.
    Johnson TB; Cain JT; White KA; Ramirez-Montealegre D; Pearce DA; Weimer JM
    Nat Rev Neurol; 2019 Mar; 15(3):161-178. PubMed ID: 30783219
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Generation of pathogenic TPP1 mutations in human stem cells as a model for neuronal ceroid lipofuscinosis type 2 disease.
    Ma L; Prada AM; Schmidt M; Morrow EM
    Stem Cell Res; 2021 May; 53():102323. PubMed ID: 33845243
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Case report: Analysis of novel compound heterozygous
    Miao SB; Guo H; Kong DX; Zhao YY; Pan SH; Jiang Y; Gao X; Wu XH
    Front Genet; 2022; 13():937485. PubMed ID: 36118858
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mutations in classical late infantile neuronal ceroid lipofuscinosis disrupt transport of tripeptidyl-peptidase I to lysosomes.
    Steinfeld R; Steinke HB; Isbrandt D; Kohlschütter A; Gärtner J
    Hum Mol Genet; 2004 Oct; 13(20):2483-91. PubMed ID: 15317752
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A novel CLN2/TPP1 mutation in a patient with late infantile neuronal ceroid lipofuscinosis.
    Yu F; Liu XM; Chen YH; Zhang SQ; Wang K
    Neurol Sci; 2015 Oct; 36(10):1917-9. PubMed ID: 26032578
    [No Abstract]   [Full Text] [Related]  

  • 27. The neuronal ceroid-lipofuscinoses.
    Goebel HH
    J Child Neurol; 1995 Nov; 10(6):424-37. PubMed ID: 8576551
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Slowing late infantile Batten disease by direct brain parenchymal administration of a rh.10 adeno-associated virus expressing
    Sondhi D; Kaminsky SM; Hackett NR; Pagovich OE; Rosenberg JB; De BP; Chen A; Van de Graaf B; Mezey JG; Mammen GW; Mancenido D; Xu F; Kosofsky B; Yohay K; Worgall S; Kaner RJ; Souwedaine M; Greenwald BM; Kaplitt M; Dyke JP; Ballon DJ; Heier LA; Kiss S; Crystal RG
    Sci Transl Med; 2020 Dec; 12(572):. PubMed ID: 33268510
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evolution of the retinal function by flash-ERG in one child suffering from neuronal ceroid lipofuscinosis CLN2 treated with cerliponase alpha: case report.
    Rigaudière F; Nasser H; Pichard-Oumlil S; Delouvrier E; Lopez-Hernandez E; Milani P; Auvin S; Delanoë C
    Doc Ophthalmol; 2021 Aug; 143(1):99-106. PubMed ID: 33956290
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neuronal ceroid lipofuscinosis type 2: an Australian case series.
    Johnson AM; Mandelstam S; Andrews I; Boysen K; Yaplito-Lee J; Fietz M; Nagarajan L; Rodriguez-Casero V; Ryan MM; Smith N; Scheffer IE; Ellaway C
    J Paediatr Child Health; 2020 Aug; 56(8):1210-1218. PubMed ID: 32329550
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Late infantile neuronal ceroid lipofuscinosis: a new mutation in Arabs.
    Goldberg-Stern H; Halevi A; Marom D; Straussberg R; Mimouni-Bloch A
    Pediatr Neurol; 2009 Oct; 41(4):297-300. PubMed ID: 19748052
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intravitreal implantation of TPP1-transduced stem cells delays retinal degeneration in canine CLN2 neuronal ceroid lipofuscinosis.
    Tracy CJ; Whiting RE; Pearce JW; Williamson BG; Vansteenkiste DP; Gillespie LE; Castaner LJ; Bryan JN; Coates JR; Jensen CA; Katz ML
    Exp Eye Res; 2016 Nov; 152():77-87. PubMed ID: 27637672
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Role of Electroencephalogram (EEG) and Magnetic Resonance Imaging (MRI) Findings in Early Recognition and Diagnosis of Neuronal Ceroid Lipofuscinosis Type 2 Disease.
    Ho ML; Wirrell EC; Petropoulou K; Sakonju A; Chu D; Seratti G; Palasis S
    J Child Neurol; 2022 Dec; 37(12-14):984-991. PubMed ID: 36184928
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An integrated strategy for the diagnosis of neuronal ceroid lipofuscinosis types 1 (CLN1) and 2 (CLN2) in eleven Latin American patients.
    Kohan R; Cismondi IA; Kremer RD; Muller VJ; Guelbert N; Anzolini VT; Fietz MJ; Ramírez AM; Halac IN
    Clin Genet; 2009 Oct; 76(4):372-82. PubMed ID: 19793312
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical protocol. Administration of a replication-deficient adeno-associated virus gene transfer vector expressing the human CLN2 cDNA to the brain of children with late infantile neuronal ceroid lipofuscinosis.
    Crystal RG; Sondhi D; Hackett NR; Kaminsky SM; Worgall S; Stieg P; Souweidane M; Hosain S; Heier L; Ballon D; Dinner M; Wisniewski K; Kaplitt M; Greenwald BM; Howell JD; Strybing K; Dyke J; Voss H
    Hum Gene Ther; 2004 Nov; 15(11):1131-54. PubMed ID: 15610613
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ongoing retinal degeneration despite intraventricular enzyme replacement therapy with cerliponase alfa in late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2 disease).
    Dulz S; Schwering C; Wildner J; Spartalis C; Schuettauf F; Bartsch U; Wibbeler E; Nickel M; Spitzer MS; Atiskova Y; Schulz A
    Br J Ophthalmol; 2023 Oct; 107(10):1478-1483. PubMed ID: 35772852
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Review of Cerliponase Alfa: Recombinant Human Enzyme Replacement Therapy for Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2.
    Lewis G; Morrill AM; Conway-Allen SL; Kim B
    J Child Neurol; 2020 Apr; 35(5):348-353. PubMed ID: 31884868
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Changing Times for CLN2 Disease: The Era of Enzyme Replacement Therapy.
    Specchio N; Pietrafusa N; Trivisano M
    Ther Clin Risk Manag; 2020; 16():213-222. PubMed ID: 32280231
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Language Delay in Patients with CLN2 Disease: Could It Support Earlier Diagnosis?
    Nickel M; Gissen P; Greenaway R; Cappelletti S; Hamborg C; Ragni B; Ribitzki T; Schulz A; Tondo I; Specchio N
    Neuropediatrics; 2023 Dec; 54(6):402-406. PubMed ID: 37329878
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Investigating health-related quality of life in rare diseases: a case study in utility value determination for patients with CLN2 disease (neuronal ceroid lipofuscinosis type 2).
    Gissen P; Specchio N; Olaye A; Jain M; Butt T; Ghosh W; Ruban-Fell B; Griffiths A; Camp C; Sisic Z; Schwering C; Wibbeler E; Trivisano M; Lee L; Nickel M; Mortensen A; Schulz A
    Orphanet J Rare Dis; 2021 May; 16(1):217. PubMed ID: 33980287
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.